Relief Therapeutics Holding SA

RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

Relief Therapeutics Renews CHF 50 million Share Subscription Facility

Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth

Relief Therapeutics Announces CEO Transition

Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone

Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics

Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health

Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East

RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement

RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders

RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement

RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders

Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory

Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission

Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100

Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update

Relief Therapeutics Announces Executive Leadership Team Change

Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders

Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board

Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023

Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe

Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™ 

Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars